Physician profile
Harry H Slatch
NPI 1194875310
$2,690.94
in general payments reported to CMS, 2019-2025
27 companies · $1,268 in 2025
The $1,268 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $15.21 · 2022: $363 · 2023: $260 · 2024: $595 · 2025: $1,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,123.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $410.55 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $358.44 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Pfizer INC. | $308.21 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $285.22 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astellas Pharma US INC | $203.29 | 2022-2025 | Xtandi, Myrbetriq |
| Abbvie INC. | $139.60 | 2019-2025 | Botox |
| Tolmar, INC. | $124.03 | 2023-2025 | Eligard, Jatenzo |
| 180 Medical, INC. | $111.87 | 2023-2025 | Gentlecath |
| Endo USA, INC. | $95.75 | 2025 | Aveed, Xiaflex |
| Ferring Pharmaceuticals INC. | $80.58 | 2025 | Adstiladrin |
| Novartis Pharmaceuticals Corporation | $69.28 | 2024-2025 | |
| Boston Scientific Corporation | $65.38 | 2025 | Axonics, Ams 700 |
| Urovant Sciences INC | $58.15 | 2022 | |
| Teleflex LLC | $47.23 | 2023-2024 | Urolift |
| Coloplast Corp | $47.09 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $45.48 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $38.29 | 2022-2023 | Aveed, Xiaflex |
| Blue Earth Diagnostics | $29.74 | 2019 | |
| Urogen Pharma, INC. | $25.50 | 2024 | |
| Shionogi INC | $25.06 | 2025 | Fetroja |
| Medtronic USA, INC. | $24.95 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $19.47 | 2019 | |
| Axonics, INC. | $19.34 | 2023 | Axonics |
| Calyxo, INC. | $18.59 | 2025 | Cvac Aspiration System |
| Hollister Incorporated | $14.01 | 2023 | Onli |
| Agiliti Surgical, INC. | $13.86 | 2023 | Sonablate, Versapulse Powersuite 80w |
| Allergan, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Slatch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.